Skip to content
‹ Back to IndustriesSciences

Semi-Living Cyborg Cells Generate Hope Within the Scientific Medical Community

Did James Cameron see the future back in 1984? The Terminator may have been a cyborg piece of science fiction, but still, one portion of that movie is coming to life in the form of semi-living cyborg cells through a complex chemical process developed by scientists to mimic living cells without being able to divide…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By James Kent · · Andrew AijianBiomedical EngineeringCyborg CellsDecibio
Share

Key takeaways

01

Did James Cameron see the future back in 1984?

02

The Terminator may have been a cyborg piece of science fiction, but still, one portion of that movie is coming to life in the form of semi-living cyborg cells through a complex chemical process developed by scientists to mimic living cells without being able to divide…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Did James Cameron see the future back in 1984? The Terminator may have been a cyborg piece of science fiction, but still, one portion of that movie is coming to life in the form of semi-living cyborg cells through a complex chemical process developed by scientists to mimic living cells without being able to divide and grow.

“The cyborg cells are programmable, do not divide, and preserve essential cellular activities and gain non-native abilities,” said biomedical engineer Cheemeng Tan from the University of California, Davis.

Biomedical advancements, such as the use of AI and cell therapy, bring with them the potential for myriad applications. One such promising application is the use of cyborg cells in oncology. Lab testing on tissue samples is underway, and the hope is cyborg cells could one day be used to deliver drugs to specific parts of the body.

Where might this technology take science in the coming years? Stephane Budel, Ph.D., a Founding Partner at DeciBio, and Andrew Aijian, Ph.D., a Partner at DeciBio, a strategy and market intelligence company for the precision medicine industry, provided some clues.

Stephane and Andrew’s Thoughts

“This is a very exciting paper. The advance of cyborg cells can have several therapeutic applications. A clear one is in oncology. There has been a lot of exciting development recently with CAR Ts. And people are discussing is it going to be autologous cells that come from the patient or allogeneic cells that would be easier to work with, where you would have like a massive batch of cells that you can use.

And there is now a third type of cells you could use: cyber cells. And in this case, you add synthetic polymers. The cells retain a number of functions, but they stop dividing. You can imagine people starting to be looking at a variety of different types of polymers and a variety of different types of synthetic pathways that they do to address cancer cells and beyond.” – Budel

“Yeah, this is the first I’ve been exposed to cyborg cells. The first I’m hearing of it. And I think what will be interesting is to see how this approach gets applied to different cell types; bacterial cells, human cells, cells with different functionalities, et cetera. And you can sort of really start to explore a vast space of possibilities and how you can use these types of cells for health applications, synthetic biology, industrial applications, especially if you can introduce non-native capabilities. In the paper, they cited the ability of these cells to be more resistant to peroxide environments, which has implications in industrial applications.

There’s sort of a huge space of functionalities and capabilities that you can explore. And I’m sure that researchers will be spending a lot of time optimizing the cells and the conditions to create many novel functionalities.” – Aijian

“Something we discussed as well is the need for these cells to actually evade the immune system. And there is certainly something that you can engineer in these cells as well that will be important if you want to inject them back into humans to treat virus conditions.” – Budel

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

JK
James KentPodcast Host and Content Creator

Dependable leader and Podcaster with more than 12 years of results-oriented brand marketing and agency management experience including a broad range of competencies: Adaptive communication and presentation skills. A manager who coaches, mentors and leads. Ability to successfully work cross-functionally within every level of an organization. Strong focus on innovative marketing solutions. Outstanding client relationship building and strategic account management support. Thrives in fast-paced environments with multiple deliverables. Podcast host and content creator.

B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Waters buys MOBILion to push into the $2 billion LC-MS proteomics market

Waters buys MOBILion to push into the $2 billion LC-MS proteomics market

Waters Corporation bought MOBILion Systems and its ion mobility technology to enter LC-MS proteomics, a market Waters sizes at $2 billion. Its existing business grew 9% to $871 million on routine drug and environmental testing. Proteomics is still a research bet.

  • 01Waters' acquisition of MOBILion aims to bolster its position in the $2 billion LC-MS proteomics market.
  • 02Waters is pitching SLIM as a gas-phase separation step for proteomics workflows.
  • 03Waters' core laboratory business has seen a 9% growth to $871 million, fueled by testing demand.

Nov 4, 2026

What an ELN connects to is the real buying test

What an ELN connects to is the real buying test

As ELN adoption broadens, the real test is whether the notebook connects to other systems. Genedata argues an ELN embedded in a shared data model can reduce brittle handoffs in biologics workflows.

  • 01A survey of 150 scientists suggests reuse across disconnected systems has become a technical job, making import/export burden a practical benchmark of whether integration is working.

Nov 4, 2026

Takara Bio and SPT Labtech pair SMART-Seq kits with firefly automation scripts

Takara Bio and SPT Labtech pair SMART-Seq kits with firefly automation scripts

SPT Labtech and Takara Bio USA are teaming up to offer validated, automated workflows for library preparation, pairing Takara Bio's NGS library prep chemistries with the firefly liquid handler from SPT Labtech. Two SMART-Seq kits are available for download today. Due to ship in January 2027, the SMART-Seq mRNA Long Read Extended kit is set to be the first product to launch with a workflow tuned for firefly automation.

  • 01For sequencing cores on SPT Labtech's firefly, Takara Bio says automated workflows will be built into new kits from the start, which suggests more of the method-building could happen at the vendors before the box reaches the bench.
  • 02Whether DNA-seq and immune profiling kits arrive with firefly scripts on their launch dates will show if this becomes standard practice or stays an RNA-seq offering.

Nov 3, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

JK
James Kent

Podcast Host and Content Creator

Dependable leader and Podcaster with more than 12 years of results-oriented brand marketing and agency management experience including a broad range of competencies: Adaptive communication and presentation skills. A manager who coaches, mentors and leads. Ability to successfully work cross-functionally within every level of an organization. Strong focus on innovative marketing solutions. Outstanding client relationship building and strategic account management support. Thrives in fast-paced environments with multiple deliverables. Podcast host and content creator.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512